DUSA Pharmaceuticals, Inc.

March 06, 2009 08:30 ET

DUSA Pharmaceuticals, Inc.® to Host Fourth Quarter and Full Year 2008 Financial Results and Corporate Highlights Conference Call

WILMINGTON, MA--(Marketwire - March 6, 2009) - DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) announces that its corporate highlights and year end financial results press release will be issued on Wednesday, March 11th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

               Wednesday, March 11 - 8:30 a.m. E.T.
If calling from the US or Canada use the following toll-free number:
                        Password - DUSA

                 For International callers use

A recorded replay of the call will be available approximately
                  15 minutes following the call
               North American callers 877.863.0350
               International callers 858.244.1268

The call will be accessible on our web site approximately four hours following the call at

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or 2 actinic keratoses of the face or scalp. DUSA is also researching additional indications for Levulan PDT, including oral leukoplakia in collaboration with the National Institutes of Health (NIH) and the prevention of AKs and SCCs in immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Massachusetts. Please visit the company's Web site at for more information.